Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Liquidia Corporation

Liquidia Technologies (($LQDA)) has held its Q3 earnings call. Read on for the main highlights of the call. Liquidia Technologies’ recent earnings ...

Liquidia Technologies’ Earnings Call: Success Amid Challenges

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Liquidia Technologies, with a price target of $35.00. The c...

Current Quarter	$0.08	Next Quarter	$0.24
Current Year	$-0.89	Next Year	$0.83
QoQ Growth	+200.0%	YoY Growth	+193.3%
3Y EPS CAGR	-33.4%	Target Price	$44.00
Consensus	Buy	Upside	+51.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LQDA	$29.11	+1.93%	2.17M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LQDA	$29.11	+1.9%	2.17M
3
4
5
6

LQDA

LQDA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Liquidia Corporation Data in Excel

Get Liquidia Corporation Data in Excel